



Newron Phase III data of safinamide in Parkinsons' disease available later in July

Milan, Italy – July 17, 2007 - Newron Pharmaceuticals S.p.A. ("Newron", SWX: NWRN), a research and development company focused on novel CNS and pain therapies, today reports that since data from a 12 month extension of a phase III trial with safinamide in early PD patients, originally expected by end of June, will only become available to the company later in July, the disclosure of such data will be delayed, accordingly.

About safinamide

Safinamide is an alpha-aminoamide derivative which is orally administered. Safinamide is believed to have a novel mode of action as a dopamine modulator (comprising both selective and reversible MAO-B inhibition and also blockade of dopamine reuptake) complemented by an effect on the glutamate pathway. Studies suggest that safinamide may combine the inhibition of dopamine reuptake and MAO-B, two key mechanisms involved in the control of dopamine concentration in the brain, and inhibition of glutamate release. If regulatory approvals are obtained, Merck Serono and Newron believe that safinamide, as an adjunctive treatment to dopamine agonists and levodopa, may have a competitive advantage over current therapies for Parkinson's disease.

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A. (www.newron.com) is a biopharmaceutical company focused on novel therapies for diseases of the Central Nervous System, particularly Parkinson's disease (PD), and pain. Newron is undertaking phase III trials with safinamide, a unique molecule with multiple mechanisms of action, for the treatment of PD in conjunction with its partner, Merck Serono, which has the rights to develop the compound in PD, Alzheimer's disease, other cognitive disorders and Restless Legs Syndrome. Recent results of a six-month phase III trial of safinamide in PD demonstrated its benefit in motor symptoms and activities of daily living, as well as its improvement in cognitive function and good tolerability. Newron and Merck Serono are planning to expand the development of safinamide to exploit its potential in Alzheimer's disease. Phase II trials with safinamide in Restless Legs Syndrome have shown promising

results. Newron is also conducting a phase II programme with ralfinamide for the treatment of neuropathic pain. Phase II data lately reported suggest that ralfinamide is effective in the the treatment of this condition. The drug has potential benefit in inflammatory pain, as well. Newron’s clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform. Newron is headquartered in Bresso, near Milan, Italy. The company is listed at SWX Swiss Exchange, trading symbol NWRN.

For more information, contact:

Media	Investors and analysts
<p>Italy Luca Benatti - CEO Phone: +39 02 6103 4 626</p> <p>UK/Global media Julia Phillips Financial Dynamics Phone: +44 (0) 20 7269 7187</p> <p>Switzerland Martin Meier-Pfister The Investor Relations Firm AG Phone: +41 43 244 81 40</p>	<p>Stefan Weber - CFO Phone: +39 02 6103 46 30</p>

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Newron undertakes no obligation to publicly update or revise any forward-looking statements.